Initial Management of Upper Gastrointestinal Bleeding
Perform early endoscopy within 24 hours of presentation after initial resuscitation, and use endoscopic hemostatic therapy (thermocoagulation, clips, or sclerosant injection) for high-risk stigmata, followed by high-dose intravenous PPI therapy. 1
Immediate Resuscitation and Risk Stratification
Begin with intravenous fluid resuscitation and apply a restrictive transfusion threshold of 7-8 g/dL hemoglobin for red blood cell transfusion 2, 3. This restrictive approach improves outcomes compared to liberal transfusion strategies.
Use validated risk stratification tools immediately in the emergency department. The Glasgow-Blatchford score is particularly useful—patients with scores of 0-1 represent very low risk and can be safely discharged with outpatient follow-up rather than admission 3. This identifies patients who don't need hospitalization and avoids unnecessary resource utilization.
Pre-Endoscopic Pharmacotherapy
Administer intravenous proton pump inhibitor (PPI) therapy before endoscopy—this may downstage the endoscopic lesion and reduce the need for endoscopic intervention, though it should not delay endoscopy 1.
Give intravenous erythromycin (250 mg) 30-60 minutes before endoscopy to improve gastric emptying and visualization 3. This prokinetic agent clears the stomach of blood and clots, significantly improving the diagnostic yield and therapeutic success of endoscopy.
Critical Caveat for Suspected Variceal Bleeding
If you suspect variceal hemorrhage (cirrhosis, stigmata of liver disease), immediately start antibiotics and vasoactive drugs (octreotide or terlipressin) before endoscopy 2. Variceal bleeding carries higher mortality than nonvariceal bleeding, and these interventions reduce mortality and rebleeding risk. Note that somatostatin and octreotide are not recommended for nonvariceal ulcer bleeding 1.
Endoscopic Timing and Therapy
Perform endoscopy within 24 hours for all hospitalized patients 1. The evidence does not support routine emergent endoscopy within 12 hours for most patients, as it doesn't improve mortality, rebleeding, or need for surgery 4. However, consider earlier endoscopy (after adequate resuscitation) in patients with:
- Hemodynamic instability despite resuscitation
- Evidence of active ongoing bleeding
- High-risk features on clinical assessment
Endoscopic Treatment Algorithm Based on Stigmata
High-risk stigmata requiring endoscopic therapy 1:
- Active spurting or oozing bleeding
- Nonbleeding visible vessel
For these high-risk lesions, use combination therapy:
- Thermocoagulation or sclerosant injection (strong recommendation) 1
- Through-the-scope clips (conditional recommendation) 1
- Epinephrine injection MUST be combined with another method—never use epinephrine alone as it provides suboptimal efficacy 1
Low-risk stigmata NOT requiring endoscopic therapy 1:
- Clean-based ulcer
- Flat pigmented spot (nonprotuberant pigmented dot)
Adherent clots: Attempt targeted irrigation to dislodge the clot, then treat the underlying lesion if high-risk stigmata are revealed 1. The role of endoscopic therapy for adherent clots that cannot be dislodged is controversial—intensive PPI therapy alone may be sufficient 1.
Post-Endoscopic Management
For patients with high-risk stigmata who undergo successful endoscopic hemostasis, administer high-dose PPI therapy via intravenous loading dose followed by continuous intravenous infusion (strong recommendation, moderate-quality evidence) 1. This is a cornerstone of management that decreases both rebleeding and mortality.
The typical regimen: 80 mg IV bolus followed by 8 mg/hour continuous infusion for 72 hours, then transition to oral PPI.
After the initial 3 days of high-dose IV PPI, use twice-daily oral PPI for 14 days, then once daily 1. This stepped approach for high-risk patients reduces rebleeding compared to once-daily dosing initially.
Hospitalization Duration
Hospitalize patients who required endoscopic hemostasis for high-risk stigmata for at least 72 hours after the procedure 1. This allows monitoring for the highest-risk period for rebleeding.
Low-risk patients can be fed within 24 hours and may be discharged promptly after endoscopy 1.
Management of Treatment Failure
If rebleeding occurs, attempt a second endoscopic therapy 1. This is generally recommended before proceeding to more invasive options.
If endoscopic therapy fails after repeat attempt:
- Consider transcatheter arterial embolization (interventional radiology) as the preferred next step 1, 3
- Surgical consultation should be obtained, with surgery reserved for cases where embolization is unavailable or has failed 1
Essential Follow-Up Actions
Test all patients with bleeding peptic ulcers for Helicobacter pylori and provide eradication therapy if positive, with confirmation of eradication 1. This is critical to prevent recurrent bleeding.
Important caveat: Negative H. pylori tests obtained during acute bleeding should be repeated after resolution, as acute bleeding can cause false-negative results 1.
Antiplatelet and Anticoagulant Management
For patients on aspirin for cardiovascular prophylaxis who develop ulcer bleeding, restart aspirin as soon as cardiovascular risk outweighs bleeding risk—typically within 7 days 1. Delaying aspirin restart increases cardiovascular events and mortality.
Add PPI therapy to all patients requiring antiplatelet or anticoagulant therapy after upper GI bleeding to reduce rebleeding risk 1.
Common Pitfall to Avoid
Do not use H2-receptor antagonists (HRAs) for acute ulcer bleeding—they are explicitly not recommended and are inferior to PPIs 1. Do not perform routine second-look endoscopy, as this is not recommended and wastes resources 1.